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Introduction. Intensity Modulated Radiotherapy (IMRT) is increasingly standard for head and neck (H&N) cancer. These advances
have resulted in longer treatment times when compared to 3D Conformal Radiotherapy (3D-CRT). Volumetric Modulated Arc
Therapy (VMAT) potentially enables shorter treatment time, achieving similar dose results.
Purpose/objective. We report feasibility and acute toxicity proﬁle of patients treated with moderate hypofractionation and simul-
taneous integrated boost (SIB) by means of Image Guided (IG)-Volumetric Modulated Arc Therapy (VMAT) technique in the ﬁrst
two years from its clinical implementation at COG.
Material and methods. Treatment plans for H&N cancer using RapidArc® (Varian Medical Systems VMAT solution) and ﬁxed ﬁeld
IMRT will be compared in terms of plan quality, delivery, accuracy and efﬁciency. Also clinical indications, number of patients,
stratiﬁed for pathology and district, basic treatment plan characteristics will be presented according to updated statistics at time
of presentation. Pre-treatment quality assurance procedures and results will also be discussed.
Results. Since its introduction in April 2011, at the time of abstract submission, 225 patients have been treated or on treatment.
This corresponds to 50% of the total number of IMRT patients at COG since 2006. Target coverage (in average D98>90%) with high
sparing of organs at risk will be detailed with the ﬁnal analysis. Mean number of MU per fractions were decreased by 60% for
RapidArc® plans, thus IG procedure was performed with daily kV imaging. Moderate hypofractionation with IG-VMAT technique
showed to be safe, with a good acute toxicity proﬁle. Concerning pre-treatment QA, Gamma Agreement Index was used with a
tolerance threshold of 95% (criteria of DTA=3mm, Delta Dose=3%).
Conclusions/discussion. RapidArc® was smoothly introduced in clinical practice, results are conﬁrming expectations and the new
modality has replaced IMRT in most of the head and neck clinical indications at COG.
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